Knowledge of Implanon® users: implications for nursing care
DOI:
https://doi.org/10.15253/2175-6783.20192039700Keywords:
Knowledge; Contraception; Contraceptive Agents; Women’s Health.Abstract
Objective: to evaluate the knowledge of Implanon® users on the characteristics and side effects of the method. Methods: transversal research, with 106 Implanon® users, with data collected through a form. For bivariate analysis, the chi-square test and the likelihood ratio test were used. Results: the majority of women (91.5%) presented adequate knowledge about the fact that the method does not offer protection against sexually transmitted diseases. Regarding the side effects, 35.8% presented moderate knowledge. Years of study showed association with inadequate knowledge about the period of exchange and absence of knowledge about side effects. Time of use did not influence inadequate knowledge about characteristics and side effects. Conclusion: the majority of users presented adequate knowledge about the characteristics of the method, years of study obtained association with inadequate knowledge about the period of exchange and lack of knowledge about side effects.
References
Ministério da Saúde (BR). Relatório de recomendação - n°. 208: Implante subdérmico liberador de etonogestrel 68 mg para anticoncepção em mulheres de 15 a 19 anos de idade [Internet]. 2016 [citado 2019 jan. 09]. Disponível em: http://conitec.gov.br/images/Relatorios/2016/Relatorio_ImplanteEtonogestrel_Anticoncepo_final.pdf
Ministério da Saúde (BR). Secretaria de Atenção à Saúde, Departamento de Atenção Básica. Caderno de Atenção Básica – n°. 26: saúde sexual e reprodutiva [Internet]. 2013 [citado 2019 jan. 09]. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/saude_sexual_saude_reprodutiva.pdf
Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception. 2013; 88(4):503-8. doi: https://doi.org/10.1016/j.contraception.2013.03.004
Kukstas C. The contraceptive implant. InnovAiT: education and inspiration for general practice. 2016; 9(8):461-7. doi: https://doi.org/10.1097/GRF.0b013e318159c2f6
Pillay D, Chersich MF, Morroni C, Pleaner M, Adeagbo OA, Naidoo N, et al. User perspectives on Implanon NXT in South Africa: a survey of 12 public-sector facilities. S Afr Med J. 2017; 107(10):815-21. doi: https://doi.org/10.7196/SAMJ.2017.v107i10.12833
Øvre-Eide V, Skjeldestad F. Use pattern for contraceptive implants in Norway. Acta Obst Gynecol Scand. 2016; 95(11):1244-50. doi: https://doi-org.ez11.periodicos.capes.gov.br/10.1111/aogs.13002
Mubarik M, Jameel N, Khalil R. Knowledge, attitude and utilization of sub-dermal birth control implants among married rural women of Pakistan. Int J Res Med Sci [Internet]. 2016 [cited Jan 09, 2019]; 4(6):2229-39. Available from: https://www.ejmanager.com/mnstemps/1/khb_004_06-321.pdf?t=1544386738
Instituto Brasileiro de Geografia e Estatística. Síntese de Indicadores Sociais: uma análise das condições de vidada população brasileira: 2018 [Internet]. 2018 [citado 2019 jan. 09]. Disponível em: https://biblioteca.ibge.gov.br/visualizacao/livros/liv101629.pdf
Braga GC, Vieira CS. Anticoncepcionais reversíveis de longa duração: Implante Liberador de Etonogestrel (Implanon®). Femina [Internet]. 2015 [citado 2019 jan. 09]; 43(l):7-14. Disponível em: http://files.bvs.br/upload/S/0100-7254/2015/v43nsuppl1/a4849.pdf
Federação Brasileira das Associações de Ginecologia e Obstetrícia (Febrasgo). Contracepção reversível de longa ação. Série Orientações e recomendações [Internet]. 2016 [citado 2019 jan. 09]. Disponível em: https://www.febrasgo.org.br/media/k2/attachments/03CONTRACEPCAO_REVERSIVEL_DE_LONGA_ACAO.pdf
Almeida RAAS, Corrêa RGCF, Rolim ILTP, Hora JM, Linard AG, Coutinho NPS, et al. Knowledge of adolescents regarding sexually transmitted infections and pregnancy. Rev Bras Enferm. 2017; 70(5):1033-9. doi: https://dx.doi.org/10.1590/0034-7167-2016-0531
Almeida RAAS, Corrêa RGCF, Rolim ILTP, Hora JM, Linard AG, Coutinho NPS, et al. Knowledge of adolescents regarding sexually transmitted infections and pregnancy. Rev Bras Enferm. 2017; 70(5):1033-9. doi: https://dx.doi.org/10.1590/0034-7167-2016-0531
Nageso A, Gebretsadik A. Discontinuation rate of Implanon and its associated factors among women who ever used Implanon in Dale District, Southern Ethiopia. BMC Women’s Health. 2018; 18(1):189. doi: https://dx.doi.org/10.1186/s12905-018-0678-x
Banafa NS, Al-Hanshi AS, Almualm Y, Alkathiri, MO. Knowledge and attitude about side effect of implanon (implant) among women attend Primary Health Center - Al-Mukalla District, Yemen. Acta Sci Med Sci [Internet]. 2017 [cited Jan 9, 2019]; 1(1):32-7. Available from: https://actascientific.com/ASMS/pdf/ASMS-01-0009.pdf
Manica D, Nucci M, Sob a pele: implantes subcutâneos, hormônios e gênero. Horiz Antropol. 2017; 23(47):93-129. doi: https://dx.doi.org/10.1590/s0104-71832017000100004
Averbach S, Kakaire O, Kayiga H, Lester F, Sokoloff A, Byamugisha J, et al. Immediate versus delayed postpartum use of levonorgestrel contraceptive implants: a randomized controlled trial in Uganda. Am J Obstet Gynecol. 2017; 217(5):568.e1-568.e7. doi: https://doi.org/10.1016/j.ajog.2017.06.005
